{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:30:01Z","timestamp":1785259801406,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cardfail.2024.08.046","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:56:19Z","timestamp":1729004179000},"page":"456-463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-8070","authenticated-orcid":false,"given":"MICHELLE WEISFELNER","family":"BLOOM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACQUELINE B.","family":"VO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JO E.","family":"RODGERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALANA M.","family":"FERRARI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANJU","family":"NOHRIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANITA","family":"DESWAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RICHARD K.","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHELLE M.","family":"KITTLESON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JENICA N.","family":"UPSHAW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NICOLAS","family":"PALASKAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNE","family":"BLAES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHERRY-ANN","family":"BROWN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BONNIE","family":"KY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"LENIHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATHEW S.","family":"MAURER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANECITA","family":"FADOL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KERRY","family":"SKURKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINE","family":"CAMBARERI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANA","family":"BARAC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cardfail.2024.08.046_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.cardfail.2024.08.046_bib0002","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood-2012-03-413112","article-title":"CyBorD: stellar response rates in AL amyloidosis","volume":"119","author":"Merlini","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cardfail.2024.08.046_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"10.1016\/j.cardfail.2024.08.046_bib0004","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cardfail.2024.08.046_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cardfail.2024.08.046_bib0006","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis","volume":"7","author":"Barrett","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.cardfail.2024.08.046_bib0007","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.cardfail.2024.08.046_bib0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.cardfail.2024.08.046_bib0009","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.cardfail.2024.08.046_bib0010","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis","volume":"22","author":"Quarta","year":"2021","journal-title":"European heart journal cardiovascular Imaging"},{"issue":"24","key":"10.1016\/j.cardfail.2024.08.046_bib0011","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cardfail.2024.08.046_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-019-0193-9","article-title":"Two types of amyloidosis presenting in a single patient: a case series","volume":"9","author":"Sidiqi","year":"2019","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.cardfail.2024.08.046_bib0013","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","journal-title":"J AM Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cardfail.2024.08.046_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.cardfail.2024.08.046_bib0015","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.cardfail.2024.08.046_bib0016","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cardfail.2024.08.046_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225","article-title":"Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis","volume":"14","author":"Witteles","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.cardfail.2024.08.046_bib0018","first-page":"472","article-title":"A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"10.1016\/j.cardfail.2024.08.046_bib0019","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cardfail.2024.08.046_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC CardioOncol."},{"issue":"24","key":"10.1016\/j.cardfail.2024.08.046_bib0021","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.cardfail.2024.08.046_bib0022","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/13506129.2022.2031963","article-title":"Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution","volume":"29","author":"Chiu","year":"2022","journal-title":"Amyloid"},{"issue":"20","key":"10.1016\/j.cardfail.2024.08.046_bib0023","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.cardfail.2024.08.046_bib0024","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","article-title":"Perspectives in treatment of AL amyloidosis","volume":"140","author":"Wechalekar","year":"2008","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.cardfail.2024.08.046_bib0025","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cardfail.2024.08.046_bib0026","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cardfail.2024.08.046_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050690","article-title":"Pretransplant Cardiac Evaluation Using Novel Technology","volume":"8","author":"Hemu","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.cardfail.2024.08.046_bib0028","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cardfail.2024.08.046_bib0029","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.cardfail.2024.08.046_bib0030","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cardfail.2024.08.046_bib0031","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cardfail.2024.08.046_bib0032","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.cardfail.2024.08.046_bib0033","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0034","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"24","key":"10.1016\/j.cardfail.2024.08.046_bib0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"31","key":"10.1016\/j.cardfail.2024.08.046_bib0036","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.cardfail.2024.08.046_bib0037","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.cardfail.2024.08.046_bib0038","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0039","doi-asserted-by":"crossref","unstructured":"Porcari A, Cappelli F, Nitsche C, Tomasani D, Sinigiani G, Longhi S, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. 2024;83(24):2411-2422. doi:10.1016\/j.jacc.2024.03.429","DOI":"10.1016\/j.jacc.2024.03.429"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2024.06.009","article-title":"Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy","author":"Lang","year":"2024","journal-title":"J Card Fail"},{"issue":"5","key":"10.1016\/j.cardfail.2024.08.046_bib0041","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.cardfail.2024.08.046_bib0042","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cardfail.2024.08.046_bib0043","first-page":"115","article-title":"How to Identify Cardiac Amyloidosis Patients Who Might Benefit From Cardiac Transplantation","volume":"11","author":"Ambardekar","year":"2023","journal-title":"JACC: Heart Failure"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0044","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"issue":"14","key":"10.1016\/j.cardfail.2024.08.046_bib0045","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.cardfail.2024.08.046_bib0046","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.cardfail.2024.08.046_bib0047","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0048","unstructured":"Dexamethasone FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/11664slr062_decadron_lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0049","unstructured":"U.S. Food and Drug Administration. Bortezomib [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021602s040lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0050","unstructured":"U.S. Food and Drug Administration. Carfilzomib [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202714lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0051","unstructured":"U.S. Food and Drug Administration. Ixazomib [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208462lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0052","unstructured":"Lenolidomide FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021880s057lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0053","unstructured":"Pomalidomide FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204026s019lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.046_bib0054","unstructured":"U.S. Food and Drug Administration. Cyclophosphamide [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212501s000lbl.pdf"},{"issue":"6","key":"10.1016\/j.cardfail.2024.08.046_bib0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.cardfail.2024.08.046_bib0056","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41409-020-0990-6","article-title":"Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation","volume":"56","author":"Al Saleh","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.cardfail.2024.08.046_bib0057","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cardfail.2024.08.046_bib0058","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cardfail.2024.08.046_bib0059","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cardfail.2024.08.046_bib0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:55:07Z","timestamp":1739321707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916424003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1071916424003646"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.046","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}